Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma

Cabozantinib (Cabometyx, Exelixis) received an expanded indication from the US Food and Drug Administration (FDA) on December 19 as a first-line treatment in patients with advanced […]